サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：急性偏頭痛治療の世界市場：薬品タイプ別 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
市場調査レポート
商品コード
1208551

急性偏頭痛治療の世界市場：薬品タイプ別 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Acute Migraine Treatment Market (Drug Type: Triptans, CGRP Antagonist, NSAID Drugs, Beta-adrenergic Blockers, Ergot Alkaloids, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 180 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
急性偏頭痛治療の世界市場：薬品タイプ別 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
出版日: 2022年12月26日
発行: Transparency Market Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の急性偏頭痛治療市場について調査分析し、市場動向、セグメント分析、地域分析、企業プロファイルなどを提供しています。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界の急性片頭痛治療市場

第4章 市場の概要

  • イントロダクション
    • 薬品タイプの定義
    • 業界の進化/発展
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 世界の急性片頭痛治療市場の分析と予測（2017年～2031年）

第5章 主要考察

  • 主な業界イベント
  • パイプライン分析
  • 規制シナリオ：/世界：地域別
  • 業界に対するCOVID-19パンデミックの影響（バリューチェーンと短/中/長期の影響）

第6章 世界の急性片頭痛治療市場の分析と予測：薬品タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額の予測：薬品タイプ別（2017年～2031年）
    • トリプタン
    • CGRP拮抗薬
    • NSAID薬品
    • βアドレナリン遮断薬
    • 麦角アルカロイド
    • その他
  • 市場魅力分析：薬品タイプ別

第7章 世界の急性片頭痛治療市場の分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額の予測：投与経路別（2017年～2031年）
    • 経口
    • 注射
    • その他
  • 市場魅力分析：投与経路別

第8章 世界の急性片頭痛治療市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額の予測：流通チャネル別（2017年～2031年）
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場魅力分析：流通チャネル別

第9章 世界の急性片頭痛治療市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額の予測：地域別（2017年～2031年）
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析：地域別

第10章 北米の急性片頭痛治療市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場金額の予測：薬品タイプ別（2017年～2031年）
  • 市場金額の予測：投与経路別（2017年～2031年）
  • 市場金額の予測：流通チャネル別（2017年～2031年）
  • 市場金額の予測：国別（2017年～2031年）
    • 米国
    • カナダ
  • 市場魅力分析
    • 薬品タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別

第11章 欧州の急性片頭痛治療市場の分析と予測

第12章 アジア太平洋の急性片頭痛治療市場の分析と予測

第13章 ラテンアメリカの急性片頭痛治療市場の分析と予測

第14章 中東・アフリカの急性片頭痛治療市場の分析と予測

第15章 競合情勢

  • 市場企業 - 競合マトリックス：階層・企業規模別
  • 市場シェア分析：企業別（2021年）
  • 企業プロファイル
    • Teva Pharmaceutical
    • Hoffmann-La Roche Ltd.
    • Johnson and Johnson
    • Amgen
    • AstraZeneca
    • Pfizer, Inc.
    • Merck & Co.
    • Novartis AG
    • Allergan plc
    • Eli Lilly and Company
    • AbbVie
    • BioDelivery Sciences International, Inc.
図表

List of Tables

  • Table 01: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 02: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 06: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 07: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 08: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 09: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 10: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 11: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 14: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 15: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 18: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 19: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 20: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 22: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 23: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 24: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 03: Global Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 04: Global Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 05: Global Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 06: Global Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 07: Global Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 08: Global Acute Migraine Treatment Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 09: Global Acute Migraine Treatment Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 10: North America Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 11: North America Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 12: North America Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 13: North America Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 14: North America Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 15: North America Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 16: North America Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 17: North America Acute Migraine Treatment Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 18: North America Acute Migraine Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 19: Europe Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 20: Europe Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 21: Europe Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 22: Europe Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 23: Europe Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 24: Europe Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 25: Europe Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 26: Europe Acute Migraine Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 27: Europe Acute Migraine Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 28: Asia Pacific Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 29: Asia Pacific Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 30: Asia Pacific Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 31: Asia Pacific Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 32: Asia Pacific Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 33: Asia Pacific Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 34: Asia Pacific Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 35: Asia Pacific Acute Migraine Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 36: Asia Pacific Acute Migraine Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 37: Latin America Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 38: Latin America Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 39: Latin America Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 40: Latin America Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 41: Latin America Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 42: Latin America Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 43: Latin America Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 44: Latin America Acute Migraine Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 45: Latin America Acute Migraine Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 46: Middle East & Africa Acute Migraine Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 47: Middle East & Africa Acute Migraine Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 48: Middle East & Africa Acute Migraine Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 49: Middle East & Africa Acute Migraine Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
  • Figure 50: Middle East & Africa Acute Migraine Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 51: Middle East & Africa Acute Migraine Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 52: Middle East & Africa Acute Migraine Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 53: Middle East & Africa Acute Migraine Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 54: Middle East & Africa Acute Migraine Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 55: Global Acute Migraine Treatment Market Share Analysis, by Company, 2021
目次
Product Code: TMRGL85296

The report provides revenue of the global acute migraine treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute migraine treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the acute migraine treatment market.

The report delves into the competitive landscape of the global acute migraine treatment market. Key players operating in the global acute migraine treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global acute migraine treatment market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Acute Migraine Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Acute Migraine Treatment Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Key Industry Events
  • 5.2. Pipeline Analysis
  • 5.3. Regulatory Scenario by Region/Globally
  • 5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global Acute Migraine Treatment Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2017-2031
    • 6.3.1. Triptans
    • 6.3.2. CGRP Antagonist
    • 6.3.3. NSAID Drugs
    • 6.3.4. Beta-adrenergic Blockers
    • 6.3.5. Ergot Alkaloids
    • 6.3.6. Others
  • 6.4. Market Attractiveness Analysis, by Drug Type

7. Global Acute Migraine Treatment Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Injection
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Acute Migraine Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Acute Migraine Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Acute Migraine Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Type, 2017-2031
    • 10.2.1. Triptans
    • 10.2.2. CGRP Antagonist
    • 10.2.3. NSAID Drugs
    • 10.2.4. Beta-adrenergic Blockers
    • 10.2.5. Ergot Alkaloids
    • 10.2.6. Others
  • 10.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.3.1. Oral
    • 10.3.2. Injection
    • 10.3.3. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Type
    • 10.6.2. By Route of Administration
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Acute Migraine Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Type, 2017-2031
    • 11.2.1. Triptans
    • 11.2.2. CGRP Antagonist
    • 11.2.3. NSAID Drugs
    • 11.2.4. Beta-adrenergic Blockers
    • 11.2.5. Ergot Alkaloids
    • 11.2.6. Others
  • 11.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.3.1. Oral
    • 11.3.2. Injection
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Type
    • 11.6.2. By Route of Administration
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Acute Migraine Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Type, 2017-2031
    • 12.2.1. Triptans
    • 12.2.2. CGRP Antagonist
    • 12.2.3. NSAID Drugs
    • 12.2.4. Beta-adrenergic Blockers
    • 12.2.5. Ergot Alkaloids
    • 12.2.6. Others
  • 12.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.3.1. Oral
    • 12.3.2. Injection
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Type
    • 12.6.2. By Route of Administration
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Acute Migraine Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Type, 2017-2031
    • 13.2.1. Triptans
    • 13.2.2. CGRP Antagonist
    • 13.2.3. NSAID Drugs
    • 13.2.4. Beta-adrenergic Blockers
    • 13.2.5. Ergot Alkaloids
    • 13.2.6. Others
  • 13.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.3.1. Oral
    • 13.3.2. Injection
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Type
    • 13.6.2. By Route of Administration
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Acute Migraine Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Type, 2017-2031
    • 14.2.1. Triptans
    • 14.2.2. CGRP Antagonist
    • 14.2.3. NSAID Drugs
    • 14.2.4. Beta-adrenergic Blockers
    • 14.2.5. Ergot Alkaloids
    • 14.2.6. Others
  • 14.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.3.1. Oral
    • 14.3.2. Injection
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Type
    • 14.6.2. By Route of Administration
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2021)
  • 15.3. Company Profiles
    • 15.3.1. Teva Pharmaceutical
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Hoffmann-La Roche Ltd.
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Johnson and Johnson
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Amgen
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. AstraZeneca
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
    • 15.3.6. Pfizer, Inc.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
    • 15.3.7. Merck & Co.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
    • 15.3.8. Novartis AG
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
    • 15.3.9. Allergan plc
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
    • 15.3.10. Eli Lilly and Company
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
    • 15.3.11. AbbVie
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. SWOT Analysis
    • 15.3.12. BioDelivery Sciences International, Inc.
      • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. Financial Overview
      • 15.3.12.4. SWOT Analysis